Kwang Sung Kim;Yang-Je Cho;Hong-Jin Kim;Na Gyong Lee;Jin-Wook Jang;Hyoung Jin Kim
发明人:
Hong-Jin Kim,Na Gyong Lee,Yang-Je Cho,Jin-Wook Jang,Hyoung Jin Kim,Kwang Sung Kim
申请号：
US13379212
公开号：
US09566323B2
申请日:
2009.10.20
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof； and (ii) a deacylated non-toxic lipooligosaccharide (LOS)； and (b) a pharmaceutically acceptable carrier； and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.
